Myasthenia gravis (MG) is an autoimmune neuromuscular disease that causes skeletal muscle weakening in the arms and legs. Myasthenia gravis causes double vision, facial paralysis, trouble walking, and eyelid drooping. Testing such as repeated nerve stimulation, blood tests for antibodies, edrophonium tests, computed tomography (CT), and magnetic resonance imaging (MRI) are used to identify this condition (MRI). MG is treated with corticosteroids (azathioprine and cyclosporine) and acetylcholine esterase inhibitors (Edrophonium and Pyridostigmine).
Market Drivers for Myasthenia Gravis Treatment
The market for Myasthenia Gravis Treatment Market is predicted to rise due to consistent research and development efforts. For example, the US Food and Drug Administration approved Alexion Pharmaceuticals, Inc.'s Soliris, which contains eculizumab as an active ingredient, in October 2017. This medication is used to treat antibody-positive generalized myasthenia gravis, as well as paroxysmal nocturnal hemoglobinuria (PNH), and atypical hemolytic uremic syndrome (aHUS).
Market Restraints for Myasthenia Gravis Treatment
Market Restraints for Myasthenia Gravis Treatment
The market for myasthenia gravis treatment is projected to be hampered by side effects from the medications used to treat the disease. According to a report published in April 2019 by BioNews Services, LLC, high dose combinations of cholinesterase inhibitors (ChEIs) and calcineurin inhibitors (CNIs) like Mestinon and Prograf are to blame for severe muscle cramps in myasthenia gravis patients. As a result, this factor is predicted to stifle the market for myasthenia gravis treatments.
Regional Analysis of the Myasthenia Gravis Treatment Market
Regional Analysis of the Myasthenia Gravis Treatment Market
The global myasthenia gravis therapy market is divided into North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa based on region.
Over the projected period, North America is expected to maintain its dominance in the myasthenia gravis therapy market. This is due to the rising prevalence and incidence of myasthenia gravis in the United States. According to the National Center for Biotechnology Information (NCBI), the incidence of myasthenia gravis in the United States was approximately 5 to 30 cases per million person-years in October 2018, and the frequency was around 10 to 20 cases per 100,000 people.
0 Comments